臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

关于TAIR
	计画说明

浏览
	典藏机构
	作者
	题名
	日期
	统计图表
	机构即时统计
	学术趋势

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作权
	出版社及期刊政策查询
	TAIR著作权会议记录

相关连结
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"lin z z"的相关文件

回到依作者浏览
依题名排序	依日期排序

显示项目 126-175 / 330 (共7页)
<< < 1 2 3 4 5 6 7 > >>
每页显示[10|25|50]项目

机构	日期	题名	作者
臺大學術典藏	2021-05-02T03:29:26Z	Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life	Hsieh C.-C.;Ho C.-C.;Lin Z.-Z.;Chong-Jen Yu;Jow G.-M.;Huang F.-Y.;Shih J.-Y.;Hsiao F.-H.; Hsieh C.-C.; Ho C.-C.; Lin Z.-Z.; CHONG-JEN YU; Jow G.-M.; Huang F.-Y.; Shih J.-Y.; Hsiao F.-H.
臺大學術典藏	2021-04-29T05:09:17Z	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy	Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; KUAN-YU CHEN; Lin Z.-Z.; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C.
臺大學術典藏	2021-04-29T05:09:15Z	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment	Huang C.-L.; Yang C.-H.; Yeh K.-H.; Hu F.-C.; KUAN-YU CHEN; Shih J.-Y.; Lin Z.-Z.; Yu C.-J.; Cheng A.-L.; Yang P.-C.
臺大學術典藏	2021-04-29T05:08:55Z	Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib	Yao Z.-H.; Liao W.-Y.; Ho C.-C.; KUAN-YU CHEN; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.H.; Yu C.-J.
臺大學術典藏	2021-04-29T05:08:51Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Hsu C.-L.;Yang C.-Y.;Kuan-Yu Chen;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; Hsu C.-L.; Yang C.-Y.; KUAN-YU CHEN; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2021-04-29T05:08:51Z	Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients	Yao Z.-H.;Liao W.-Y.;Ho C.-C.;Kuan-Yu Chen;Shih J.-Y.;Chen J.-S.;Lin Z.-Z.;Lin C.-C.;Yang J.C.-H.;Yu C.-J.; Yao Z.-H.; Liao W.-Y.; Ho C.-C.; KUAN-YU CHEN; Shih J.-Y.; Chen J.-S.; Lin Z.-Z.; Lin C.-C.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2021-04-27T08:36:02Z	The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia	HUNG-YANG KUO; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏	2021-04-27T08:11:51Z	The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia	HUNG-YANG KUO; Lin Z.-Z.; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; Shao Y.-Y.; Hsu C.; Cheng W.-F.; Cheng A.-L.; Yang J.C.H.; Lai M.-S.
臺大學術典藏	2021-04-23T05:56:29Z	Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer	Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Chih-Hsin Yang;Cheng A.-L.;Kuo S.-H.; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; CHIH-HSIN YANG; Cheng A.-L.; Kuo S.-H.
臺大學術典藏	2021-03-19T06:57:53Z	Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment	Lin Z.-Z.; Hsu C.; YEUN-CHUNG CHANG; Yu C.-J.; Hsu C.-H.; Lin C.-C.; Cheng A.-L.; Yang P.-C.; Yang C.-H.
臺大學術典藏	2021-03-19T06:57:52Z	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy	Yang C.-H.; Yu C.-J.; Shih J.-Y.; YEUN-CHUNG CHANG; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; Lin Z.-Z.; Huang C.-J.; Shun C.-T.; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C.
臺大學術典藏	2021-03-19T01:54:20Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	TSUNG-HAO LIU; Shao Y.-Y.; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-19T01:54:19Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.; TSUNG-HAO LIU; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-18T03:23:39Z	The impact of diabetes mellitus on prognosis of early breast cancer in Asia	WEI-WU CHEN; Shao Y.-Y.; Shau W.-Y.; Lin Z.-Z.; Lu Y.-S.; Chen H.-M.; Kuo R.N.C.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-03-18T02:03:01Z	Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy	Yang C.-H.; Yu C.-J.; Shih J.-Y.; Chang Y.-C.; Hu F.-C.; Tsai M.-C.; Chen K.-Y.; Lin Z.-Z.; Huang C.-J.; CHIA-TUNG SHUN; Huang C.-L.; Bean J.; Cheng A.-L.; Pao W.; Yang P.-C.
臺大學術典藏	2021-03-15T07:44:49Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; LI-CHUN LU; Lin Z.-Z.; Hsu C.; Shen Y.-C.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:48Z	Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma	LI-CHUN LU; Shao Y.-Y.; Kuo R.N.C.; Lin Z.-Z.; Yeh Y.-C.; Shau W.-Y.; Hsu C.-H.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-03-15T07:44:44Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.;Shao Y.-Y.;Li-Chun Lu;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; Shao Y.-Y.; LI-CHUN LU; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-15T07:44:43Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.;Liu T.-H.;Hsu C.;Li-Chun Lu;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; Shao Y.-Y.; Liu T.-H.; Hsu C.; LI-CHUN LU; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H.
臺大學術典藏	2021-03-15T06:27:34Z	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy	Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; DWANG-YING CHANG; Yang C.-H.; Hong R.-L.; Hsu C.-H.; Chengb A.-L.
臺大學術典藏	2021-03-09T06:46:07Z	A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor	Yang S.-H.; Lin C.-C.; Lin Z.-Z.; Tseng Y.-L.; RUEY-LONG HONG
臺大學術典藏	2021-03-09T06:46:06Z	Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy	Lin Z.-Z.; Hsu C.; Hu F.-C.; Shao Y.-Y.; Chang D.-Y.; Yang C.-H.; RUEY-LONG HONG; Hsu C.-H.; Chengb A.-L.
臺大學術典藏	2021-03-09T05:27:30Z	Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival	Ying-Chun Shen; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; Chang M.-C.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:37Z	Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma	Hsu C.-H.; Ying-Chun Shen; Lin Z.-Z.; Chen P.-J.; Shao Y.-Y.; Ding Y.-H.; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:36Z	Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma	Shao Y.-Y.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:34Z	High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy	Shao Y.-Y.; Lin Z.-Z.; Chen T.-J.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:33Z	Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems	Shao Y.-Y.; Lu L.-C.; Lin Z.-Z.; Hsu C.; Ying-Chun Shen; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:32Z	Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer	Ying-Chun Shen; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; Yeh K.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:31Z	Considerations of heterogeneity in clinical trials for hepatocellular carcinoma	Liu T.-H.; Shao Y.-Y.; Lu L.-C.; Ying-Chun Shen; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L.
臺大學術典藏	2021-03-09T05:18:29Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Ying-Chun Shen; Shao Y.-Y.; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏	2021-03-05T06:07:28Z	Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival	Shen Y.-C.; Hu F.-C.; Jeng Y.-M.; Chang Y.-T.; Lin Z.-Z.; MING-CHU CHANG; Hsu C.; Cheng A.-L.
臺大學術典藏	2021-02-25T07:00:58Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Yu-Yun Shao;Hsu C.-H.;Cheng A.-L.;Lee R.-C.;Chao Y.;Hsu C.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L.; Lee R.-C.; Chao Y.; Hsu C.
臺大學術典藏	2021-02-23T08:26:36Z	The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma	Lin Z.-Z.;Hsu H.-C.;Hsu C.-H.;Yeh P.-Y.;Huang C.-Y.F.;Huang Y.-F.;Chen T.-J.;Sung-Hsin Kuo;Hsu C.;Hu F.-C.;Jeng Y.-M.;Chung Y.;Cheng A.-L.; Lin Z.-Z.; Hsu H.-C.; Hsu C.-H.; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; SUNG-HSIN KUO; Hsu C.; Hu F.-C.; Jeng Y.-M.; Chung Y.; Cheng A.-L.
臺大學術典藏	2021-02-23T08:26:35Z	Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma	Yang S.-H.; Lin Z.-Z.; SUNG-HSIN KUO; Cheng A.-L.
臺大學術典藏	2021-02-23T08:26:23Z	The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases	Chiang Y.;Yang J.C.-H.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Lin Z.-Z.;Lan K.-H.;Cheng A.-L.;Sung-Hsin Kuo; Chiang Y.; Yang J.C.-H.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Lin Z.-Z.; Lan K.-H.; Cheng A.-L.; SUNG-HSIN KUO
臺大學術典藏	2021-02-23T08:26:10Z	Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer	Yang W.-C.;Hsu F.-M.;Chen Y.-H.;Shih J.-Y.;Yu C.-J.;Lin Z.-Z.;Lu S.-H.;Yang J.C.-H.;Cheng A.-L.;Sung-Hsin Kuo; Yang W.-C.; Hsu F.-M.; Chen Y.-H.; Shih J.-Y.; Yu C.-J.; Lin Z.-Z.; Lu S.-H.; Yang J.C.-H.; Cheng A.-L.; SUNG-HSIN KUO
臺大學術典藏	2021-02-18T02:33:48Z	Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma	Shao Y.-Y.;Liu T.-H.;Chiun Hsu;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.; Shao Y.-Y.; Liu T.-H.; Chiun Hsu; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.
臺大學術典藏	2021-02-18T02:33:48Z	Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma	Lin Z.-Z.;Chiun Hsu;Jeng Y.-M.;Hu F.-C.;Pan H.-W.;Wu Y.-M.;Hsu H.-C.;Cheng A.-L.; Lin Z.-Z.; Chiun Hsu; Jeng Y.-M.; Hu F.-C.; Pan H.-W.; Wu Y.-M.; Hsu H.-C.; Cheng A.-L.
臺大學術典藏	2021-02-18T01:45:21Z	A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy	Lin Z.-Z.;Chen B.-B.;Hung Y.-P.;Huang P.-H.;Shen Y.-C.;Shao Y.-Y.;Chiun Hsu;Cheng A.-L.;Lee R.-C.;Chao Y.; Lin Z.-Z.; Chen B.-B.; Hung Y.-P.; Huang P.-H.; Shen Y.-C.; Shao Y.-Y.; Chiun Hsu; Cheng A.-L.; Lee R.-C.; Chao Y.
臺大學術典藏	2021-01-28T01:06:53Z	Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma	Huang C.-L.;Lin Z.-Z.;Su I.-J.;Chao T.-Y.;Tien H.-F.;Chang M.-C.;Huang M.-C.;Kao W.-Y.;Tang J.-L.;Kun-Huei Yeh;Wang C.-H.;Hsu C.-H.;Liu M.-Y.;Cheng A.-L.; Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; Tang J.-L.; KUN-HUEI YEH; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L.
臺大學術典藏	2021-01-28T01:06:43Z	EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment	Huang C.-L.; Yang C.-H.; KUN-HUEI YEH; Hu F.-C.; Chen K.-Y.; Shih J.-Y.; Lin Z.-Z.; Yu C.-J.; Cheng A.-L.; Yang P.-C.
臺大學術典藏	2021-01-28T01:06:34Z	Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer	Chen K.-H.;Shao Y.-Y.;Lin Z.-Z.;Yeh Y.-C.;Wen-Yi S.;Kuo R.N.;Chen H.-M.;Lai C.-L.;Kun-Huei Yeh;Cheng A.-L.;Lai M.-S.; Chen K.-H.; Shao Y.-Y.; Lin Z.-Z.; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; KUN-HUEI YEH; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-01-28T01:06:34Z	Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer	Shen Y.-C.;Li C.-P.;Yen C.-J.;Hsu C.;Lin Y.-L.;Lin Z.-Z.;Chen L.-T.;Su W.-C.;Chao Y.;Kun-Huei Yeh;Cheng A.-L.; Shen Y.-C.; Li C.-P.; Yen C.-J.; Hsu C.; Lin Y.-L.; Lin Z.-Z.; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH; Cheng A.-L.
臺大學術典藏	2021-01-28T01:06:30Z	Young patients with colorectal cancer have increased risk of second primary cancers	Liang Y.-H.; Shao Y.-Y.; Chen H.-M.; Lai C.-L.; Lin Z.-Z.; Kuo R.N.; Cheng A.-L.; KUN-HUEI YEH; Lai M.-S.
臺大學術典藏	2021-01-28T01:06:29Z	Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan	Shao Y.-Y.; Hsu C.-H.; KUN-HUEI YEH; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S.
臺大學術典藏	2021-01-28T01:06:27Z	Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study	Chen K.-H.; Shao Y.-Y.; Chen H.-M.; Lin Y.-L.; Lin Z.-Z.; Lai M.-S.; Cheng A.-L.; KUN-HUEI YEH
臺大學術典藏	2021-01-06T03:58:57Z	Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma	Huang C.-L.; Lin Z.-Z.; Su I.-J.; Chao T.-Y.; Tien H.-F.; Chang M.-C.; Huang M.-C.; Kao W.-Y.; JIH-LUH TANG; Yeh K.-H.; Wang C.-H.; Hsu C.-H.; Liu M.-Y.; Cheng A.-L.
臺大學術典藏	2021-01-04T12:13:04Z	Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma	Liu M.-Y.; Cheng A.-L.; Hsu C.-H.; Wang C.-H.; Tang J.-L.; Yeh K.-H.; Kao W.-Y.; Huang M.-C.; Chang M.-C.; HWEI-FANG TIEN; Chao T.-Y.; Lin Z.-Z.; Su I.-J.; Huang C.-L.
臺大學術典藏	2020-12-24T03:18:47Z	Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations	Lin Y.-T.;Chen J.-S.;Liao W.-Y.;Ho C.-C.;Chia-Lin Hsu;Yang C.-Y.;Chen K.-Y.;Lee J.-H.;Lin Z.-Z.;Shih J.-Y.;Yang J.C.-H.;Yu C.-J.; Lin Y.-T.; Chen J.-S.; Liao W.-Y.; Ho C.-C.; CHIA-LIN HSU; Yang C.-Y.; Chen K.-Y.; Lee J.-H.; Lin Z.-Z.; Shih J.-Y.; Yang J.C.-H.; Yu C.-J.
臺大學術典藏	2020-12-23T05:43:42Z	Sunitinib-induced myxedema coma	Chen S.-Y.; Kao P.-C.; Lin Z.-Z.; WEN-CHU CHIANG; Fang C.-C.

显示项目 126-175 / 330 (共7页)
<< < 1 2 3 4 5 6 7 > >>
每页显示[10|25|50]项目

	English \| 正體中文 \| 简体中文 \| 总笔数 :0
	造访人次 : 52373495 在线人数 : 1036 教育部委托研究计画计画执行:国立台湾大学图书馆